InsiderTrades.com logo

PTX Insider Trading

Insider Ownership Percentage: 15.01%
Insider Buying (Last 12 Months): A$26,405.96
Insider Selling (Last 12 Months): A$0.00

Prescient Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Prescient Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Prescient Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for PTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Prescient Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2025Gavin ShepherdInsiderBuy614,092A$0.04A$26,405.96
4/4/2023James CampbellInsiderBuy17,813A$0.06A$1,104.41
See Full Table

SEC Filings (Institutional Ownership Changes) for Prescient Therapeutics (ASX:PTX)

0.52% of Prescient Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Prescient Therapeutics logo
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.
Read More on Prescient Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

537,831 shs

Average Volume

N/A

Market Capitalization

$38.66 million

P/E Ratio

N/A

Dividend Yield

5.88%

Beta

1.19

Who are the company insiders with the largest holdings of Prescient Therapeutics?

Prescient Therapeutics' top insider shareholders include:
  1. Gavin Shepherd (Insider)
Learn More about top insider investors at Prescient Therapeutics.